Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698685 · ClinicalTrials.gov registry record · Phase 2
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
A Phase 2 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00698685 is a Phase 2 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 14 participants.
The verdict
NCT00698685, a Phase 2 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study tests the hypothesis that a purely immunosuppressive preparative regimen allows engraftment of related or unrelated allogeneic hematopoietic stem cells in subjects with high-risk malignancies, without causing the post-transplant myelosuppression (e.g., neutropenia, thrombocytopenia) that occurs with currently used reduced-intensity (nonmyeloablative) preparative regimens. This study incorporates both safety and efficacy endpoints and evaluates a novel preparative regimen of alemtuzumab plus continuous-infusion pentostatin, two immunosuppressive agents with different mechanisms of action, in recipients of related or unrelated allogeneic hematopoietic stem cell transplantation.
Interventions
- BIOLOGICAL Alemtuzumab
- PROCEDURE Allogeneic hematopoietic stem cell transplantation
- DRUG Pentostatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-01-23 |
| Est. Completion | 2011-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698685
The ClinicalTrials.gov registry entry for NCT00698685 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Alemtuzumab is the first listed.
NCT00698685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698685 about?
NCT00698685 is a clinical study titled "Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation". This study tests the hypothesis that a purely immunosuppressive preparative regimen allows engraftment of related or unrelated allogeneic hematopoietic stem cells in subjects with high-risk malignancies, without causing the post-transplant myelosuppression (e.g., neutropenia, thrombocytopenia) that ...
What is the current status of trial NCT00698685?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2006-01-23. Estimated completion is 2011-04-26.
What interventions are being tested in trial NCT00698685?
The interventions under investigation include: Alemtuzumab (BIOLOGICAL), Allogeneic hematopoietic stem cell transplantation (PROCEDURE), Pentostatin (DRUG).
Who is sponsoring clinical trial NCT00698685?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.